Dr. Pels joined the hemophilia treatment center at Yale University as a pediatric hematology/oncology resident in 2004 after receiving her undergraduate degree from Johns Hopkins and her MD from the University of Vermont College of Medicine. Her…
The latest Resource Roundup (RR) is dedicated to women, girls, and people with the propensity to menstruate (WGPPM), all historically underserved groups within the inherited bleeding disorders community. While recognition of these populations and…
Match Your Gift and Volunteer HoursDid you know you can double your support for National Bleeding Disorders Foundation, without even giving a dollar more? You can if your employer participates in a Matching Gifts Program.If you…
NBDF monitors emerging therapies and changes in the therapeutic landscape that may affect people living with bleeding disorders. One of those developments involves BioMarin’s decision to out-license (allowing another company to market and sell)…
Speakers: Merika Frazier Hawes, LMSW; Joetta Smith, RN, Chase WilliamsonHurricane Helene made landfall in the Augusta, Georgia area in the early morning hours of Friday, September 27, 2024. With wind gusts up to 80mph, the hurricane…
The commercialization of hemophilia AAV gene therapies in recent years has created a steep learning curve for clinicians, patients, and other stakeholders in the bleeding disorders community. As a novel treatment unlike any that has come before,…
#block-recentonlineeducation {
display:none;
}
Obtenga información sobre el tratamiento anti-IVFTEl tratamiento anti-IVFT constituye una nueva opción para personas que tienen hemofilia A o B, con o sin inhibidores. En este…